|Institutional Source||Beutler Lab|
|Gene Name||activin receptor IIA|
|Synonyms||ActRIIa, Acvr2, tActRII|
|Is this an essential gene?||Non essential (E-score: 0.000)|
|Stock #||R8123 (G1)|
|Chromosomal Location||48814109-48903269 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||T to C at 48873372 bp|
|Amino Acid Change||Serine to Proline at position 143 (S143P)|
|Ref Sequence||ENSEMBL: ENSMUSP00000067305 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000063886]|
|Predicted Effect||probably damaging
AA Change: S143P
PolyPhen 2 Score 0.993 (Sensitivity: 0.70; Specificity: 0.97)
AA Change: S143P
|Coding Region Coverage||
|Validation Efficiency||100% (48/48)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a receptor that mediates the functions of activins, which are members of the transforming growth factor-beta (TGF-beta) superfamily involved in diverse biological processes. The encoded protein is a transmembrane serine-threonine kinase receptor which mediates signaling by forming heterodimeric complexes with various combinations of type I and type II receptors and ligands in a cell-specific manner. The encoded type II receptor is primarily involved in ligand-binding and includes an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic serine-threonine kinase domain. This gene may be associated with susceptibility to preeclampsia, a pregnancy-related disease which can result in maternal and fetal morbidity and mortality. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jun 2013]
PHENOTYPE: While most mice homozygous for targeted mutations that inactivate this gene appear normal, a few display skeletal and facial abnormalities. As adults, follicle-stimulating hormone is suppressed, affecting reproduction. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Acvr2a||
(F):5'- TGGAAGTCACACAGCGTAAG -3'
(R):5'- CTAACAGAGTACTCAGTTATACAGCAG -3'
(F):5'- TCACACAGCGTAAGTGCATAGTG -3'
(R):5'- GTAGGCCATCTTGTGATGT -3'